Synopsis
The Committee adopted a positive opinion for a variation for Mirataz (mirtazapine) to update the product information on the basis of new target animal safety data. The Committee adopted the outcomes of the signal management process for the current month.
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at European Medicines Agency: news ↗
